Skip to main content
Premium Trial:

Request an Annual Quote

DiaSorin Molecular Gets CE Mark for Flu, RSV Assay

NEW YORK — DiaSorin Molecular said on Tuesday that it has received CE marking for its Simplexa Flu A/B & RSV Direct Gen II assay for influenza and respiratory syncytial virus (RSV).

The test is designed to run on DiaSorin Molecular's sample-to-answer Liason MDX real-time PCR instrument and can be used alone or in combination with the company's Simplexa COVID-19 Direct assay for SARS-CoV-2 infection, which received Emergency Use Authorization from the US Food and Drug Administration in March.

According to the Cypress, California-based company, influenza A, influenza B, RSV, and SARS-CoV-2 can have similar clinical presentations, and coinfection has been shown to cause increased severity of respiratory disease.

"We met our goal to have the Simplexa Flu A/B & RSV Direct Gen II assay available in time for use during the upcoming flu season and for patient samples to be tested, when needed, alongside the COVID-19 Direct assay," DiaSorin Molecular CSO Michelle Tabb said in a statement. "This flu season, the ability to detect and differentiate between influenza, RSV, and COVID-19 will be vital."

DiaSorin Molecular, a subsidiary of Italy's DiaSorin, said it has also submitted the Simplexa Flu A/B & RSV Direct Gen II assay to the FDA for 510(k) clearance.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.